Results 41 to 50 of about 682 (125)

Validation study for assessing COVID-19 pneumonia treatments [PDF]

Scientific Reports
This study investigates the effectiveness of Azvudine and nirmatrelvir-ritonavir (Paxlovid) in treating COVID-19 pneumonia through an analysis of real-world clinical data.
Kaibin Lin, Bing Zhou, Yi Wu, Zheng Wang, Shu Li, Yuanyuan Li, Fen Li, Yang Xue, Zirou Liu, Jiafen Liao   +9 more
doaj   +2 more sources

Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19

BMJ Open Respiratory Research
Background In China, both nirmatrelvir-ritonavir (Paxlovid) and azvudine have been granted approval to treat adult SARS-CoV-2-infected patients with moderate symptoms.
Junjun Chen, Zheng Zhang, Huan Zhang, Yao Li, Yan Kang, Jianbo Li, Tan Xiaojiao, Chenxi Wang, Haiqing Shi, Xiaodong Jin, Xuelian Liao   +10 more
doaj   +3 more sources

Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis

Virology Journal
Background Azvudine has been approved for the treatment of coronavirus disease 2019 (COVID-19) patients in China, and this meta-analysis aims to illustrate the safety of azvudine and its effectiveness in reducing mortality. Methods PubMed, Embase, Web of
Yaqi Wang, Huaiya Xie, Luo Wang, Junping Fan, Ying Zhang, Siqi Pan, Wangji Zhou, Qiaoling Chen, Xueqi Liu, Aohua Wu, Hong Zhang, Jinglan Wang, Xinlun Tian   +12 more
doaj   +3 more sources

Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials

Frontiers in Pharmacology, 2023
Azvudine (FNC) is a synthetic nucleoside analog used to treat adult patients living with human immunodeficiency virus-1 (HIV-1) infection with high viral load.
Ke-Wei Zhu
doaj   +1 more source

Azvudine therapy of common COVID‐19 in hemodialysis patients

Journal of Medical Virology, 2023
AbstractThere is no antiviral study on hemodialysis patients infected with coronavirus disease 2019 (COVID‐19), especially on the application of 2′‐deoxy‐2′‐β ‐fluoro‐4′‐azidocytidine (Azvudine, FNC) antiviral therapy. We conducted a multicenter observational study involving 1008 hemodialysis patients.
Shunlai Shang, Bo Fu, Yanqiu Geng, Jian Zhang, Dawei Zhang, Fenglin Xiao, Zhaojun Sheng, Jingbo Zhai, Wenge Li, Xiangmei Chen, Chunfu Zheng, Qinggang Li   +11 more
openaire   +2 more sources

Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching

Frontiers in Pharmacology, 2023
Background: Nirmatrelvir/ritonavir and azvudine have been approved for the early treatment of COVID-19 in China, however, limited real-world data exists regarding their effectiveness and safety.Methods: We conducted a retrospective cohort study involving
An-Hua Wei, Lu Zeng, Lu Wang, Lin Gui, Wen-Ting Zhang, Xue-Peng Gong, Juan Li, Dong Liu   +7 more
doaj   +1 more source

Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro.

PLoS ONE, 2014
Azvudine is a novel nucleoside reverse transcriptase inhibitor with antiviral activity on human immunodeficiency virus, hepatitis B virus and hepatitis C virus. Here we reported the in vitro activity of azvudine against HIV-1 and HIV-2 when used alone or
Rui-Rui Wang, Qing-Hua Yang, Rong-Hua Luo, You-Mei Peng, Shao-Xing Dai, Xing-Jie Zhang, Huan Chen, Xue-Qing Cui, Ya-Juan Liu, Jing-Fei Huang, Jun-Biao Chang, Yong-Tang Zheng   +11 more
doaj   +1 more source

Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study

Infectious Diseases and Therapy, 2023
Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19 in China due to their earlier approval by the National Medical Products Administration.
Qinqin Zhao, Bei Zheng, Bing Han, Pinpin Feng, Zhongni Xia, Hong Jiang, Yin Ying, Jun Zhu, Cheng Fei, Junlei Xiang, Lingli Shen, Qiliang Luo, Yinhuan Wu, Ayiguzhali Wusiman, Chuanwei Xin, Meiling Zhang, Gonghua Li, Xiang Li   +17 more
doaj   +1 more source

A Review on Medicinal Chemistry and Biological Activity of Dihydropyrimidinones Against HIV

Archiv der Pharmazie, Volume 359, Issue 4, April 2026.
This article presents the latest advances in the development of dihydropyrimidinone (DHPM) derivatives as promising candidates against HIV. By exploring their interactions with essential viral targets and highlighting innovative compounds with potent antiviral activity, we provide an updated perspective on the opportunities for new antiretroviral ...
Debora I. Leite, Fernando B. Macedo, Murilo Marinho de C. Lima, Isabelle S. Brum, Jonathan Fragoso Miranda de Oliveira, Ana Clara S. Costa, Stella C. Duarte, Sarah Moon, Stefany de Castro B. Moura, Andressa P. de Oliveira, Nubia Boechat, Monica M. Bastos   +11 more
wiley   +1 more source

Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort studyResearch in context

EClinicalMedicine, 2023
Summary: Background: As the COVID-19 pandemic continues to spread, the number of associated deaths continues to increase, especially among those with pre-existing conditions.
Yuming Sun, Liping Jin, Yating Dian, Minxue Shen, Furong Zeng, Xiang Chen, Guangtong Deng   +6 more
doaj   +1 more source